XPOT: A Promyelocytic Leukemia-Associated Protein (G11260)

Target Name: XPOT

NCBI ID: G11260

XPOT

XPOT: A Promyelocytic Leukemia-Associated Protein

XPOT (X-linked Promyelocytic leukemia-associated protein) is a protein that is expressed in the white blood cells of individuals with promyelocytic leukemia, a type of cancer that affects the bone marrow and blood cells. The protein is named after the disease it is associated with, and its high expression is one of the hallmarks of this disease.

XPOT is a transmembrane protein that is expressed in a variety of tissues and cells, including blood cells, epithelial cells, and neural cells. It is characterized by its long extracellular domain, which is composed of a variable number of repeats of the amino acid Asp. The Asp residues in the XPO3 protein are involved in its stability and functions, and several studies have identified critical roles for Asp in the regulation of cellular processes such as cell adhesion, migration, and apoptosis.

One of the most promising aspects of XPOT is its potential as a drug target. The high expression of XPOT in cancer cells makes it an attractive target for small molecule inhibitors that can reduce its levels and inhibit its functions. Several studies have shown that XPOT is sensitive to inhibitors such as 5-FU, a commonly used drug for cancer treatment, and that these inhibitors are effective in animal models of promyelocytic leukemia.

In addition to its potential as a drug target, XPOT is also a potential biomarker for the disease. The expression of XPOT is often reduced in individuals with promyelocytic leukemia, and this reduction is associated with poor prognosis and treatment outcomes. Therefore, measuring XPOT levels in blood samples or bone marrow samples could be a useful diagnostic or prognostic tool for this disease.

The structure and function of XPOT have also been extensively studied to gain a better understanding of its role in cancer. Several studies have shown that XPOT is involved in the regulation of cellular processes such as cell adhesion, migration, and apoptosis, and that these processes are disrupted in promyelocytic leukemia. These studies have identified several key features of XPOT that are important for its functions, including its long extracellular domain, which is involved in its stability and functions, and its ability to interact with other proteins.

In conclusion, XPOT is a protein that is expressed in the white blood cells of individuals with promyelocytic leukemia and has been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and apoptosis. Its high expression and stability make it an attractive target for small molecule inhibitors, and its potential as a biomarker for the disease makes it an important tool for the diagnosis and treatment of promyelocytic leukemia. Further research is needed to fully understand the role of XPOT in cancer and to develop effective treatments.

Protein Name: Exportin For TRNA

Functions: Mediates the nuclear export of aminoacylated tRNAs. In the nucleus binds to tRNA and to the GTPase Ran in its active GTP-bound form. Docking of this trimeric complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. Upon transit of a nuclear export complex into the cytoplasm, disassembling of the complex and hydrolysis of Ran-GTP to Ran-GDP (induced by RANBP1 and RANGAP1, respectively) cause release of the tRNA from the export receptor. XPOT then return to the nuclear compartment and mediate another round of transport. The directionality of nuclear export is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus

The "XPOT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XPOT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets